Unknown PHASE4 INTERVENTIONAL 2-arm NCT00843661

Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients

Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study.

Sponsor: Merck Sharp & Dohme LLC

Conditions HIV HIV Infections Hyperlipidemia

Interventions ezetimibe fenofibrate pravastatin

Updated 6 times since 2017 Last updated: Aug 1, 2011 Started: Mar 31, 2009 Primary completion: Dec 31, 2011 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on HIV and HIV Infections, this trial is ongoing. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 6 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2021 — Jun 2022 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Ospedale di Circolo - Fondazione Macchi

Data source: Ospedale di Circolo - Fondazione Macchi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Varese, Italy